Enar

Indication:

It is indicated for the relief of signs and symptoms of osteoarthritis, rehumatoid arthritis and ankylosing spondylitis, dysmenorrhoea and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID associated gastric ulcers.

Dosage & Administration:

Enar 375 once or Enar 500 tablet twice daily.

The tablets are to be swallowed whole with liquid. Do not split, chew, crush or dissolve the tablet. The tablet is to be taken at least 30 minutes before meals.

Elderly patients: Studies indicate that although total plasma concentration of Naproxen is unchanged, the unbound plasma fraction of Naproxen is increased in the elderly. Use caution when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly use the lowest effective dose.

Patients with renal impairment: Naproxen containing products are not recommended for use in patients with moderate to severe renal impairment (creatinine clearance < 30 ml/min).  

Hepatic insufficiency: Not recommended in patients with severe hepatic impairment because Esomeprazole dose should not exceed 20 mg daily in these patients.

Preparation:

Enar 375 Tablet: Each tablet contains delayed release Naproxen BP 375 mg and immediate release Esomeprazole Magnesium Trihydrate BP equivalent to Esomeprazole 20 mg.
Enar 500 Tablet: Each tablet contains delayed release Naproxen BP 500 mg and immediate release Esomeprazole Magnesium Trihydrate BP equivalent to Esomeprazole 20 mg.